The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Halomonth (TN)     [4-(4-chlorophenyl)-1-[4-(4- fluorophenyl)...

Synonyms: SureCN120575, KD-136, AG-G-93888, CHEMBL1200986, C31H41ClFNO3, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of C13370

 

Psychiatry related information on C13370

 

High impact information on C13370

 

Chemical compound and disease context of C13370

 

Biological context of C13370

 

Anatomical context of C13370

 

Associations of C13370 with other chemical compounds

 

Gene context of C13370

 

Analytical, diagnostic and therapeutic context of C13370

References

  1. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate. Hyde, T.M., Egan, M.F., Wing, L.L., Wyatt, R.J., Weinberger, D.R., Kleinman, J.E. Psychopharmacology (Berl.) (1995) [Pubmed]
  2. Depot neuroleptics and manic depressive psychosis. Lowe, M.R., Batchelor, D.H. International clinical psychopharmacology. (1986) [Pubmed]
  3. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. Cookson, J.C., Kennedy, N.M., Gribbon, D. International clinical psychopharmacology. (1986) [Pubmed]
  4. A loading-dose strategy for converting from oral to depot haloperidol. Ereshefsky, L., Toney, G., Saklad, S.R., Anderson, C., Seidel, D. Hospital & community psychiatry. (1993) [Pubmed]
  5. Outcome of treatment with haloperidol decanoate in a patient with schizophrenia, chronic undifferentiated type, and end stage renal disease. Rueda-Vasquez, E. Military medicine. (1988) [Pubmed]
  6. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick, I.D., Marder, S.R. The Journal of clinical psychiatry. (2005) [Pubmed]
  7. Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Altamura, A.C., Tacchini, G.L., Maes, M. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (1995) [Pubmed]
  8. Treatment of refractory Tourette syndrome with haloperidol decanoate. Clarke, D.J., Ford, R. Acta psychiatrica Scandinavica. (1988) [Pubmed]
  9. The use of depot neuroleptic haloperidol decanoate. Fernando, J., Krishna Raju, R., Jones, G.G., Stanley, R.O. Acta psychiatrica Scandinavica. (1984) [Pubmed]
  10. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Nyberg, S., Farde, L., Halldin, C., Dahl, M.L., Bertilsson, L. The American journal of psychiatry. (1995) [Pubmed]
  11. Parallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration. Kurachi, M., Shibata, R., Murata, M., Tanii, Y. Biol. Psychiatry (1995) [Pubmed]
  12. Comparative study of dopamine metabolism with local cerebral glucose utilization in rat brain following the administration of haloperidol decanoate. Kurachi, M., Yasui, S., Shibata, R., Murata, M., Hagino, H., Kurachi, T., Tanii, Y., Kurata, K. Biol. Psychiatry (1994) [Pubmed]
  13. Haloperidol decanoate pharmacokinetics in red blood cells and plasma. Dysken, M.W., Kim, S.W., Vatassery, G., Johnson, S.B., Skare, S., Holden, L., Thomsyck, L. Journal of clinical psychopharmacology. (1992) [Pubmed]
  14. Comparison of effects of khat extract and amphetamine on motor behaviors in mice. Connor, J.D., Rostom, A., Makonnen, E. Journal of ethnopharmacology. (2002) [Pubmed]
  15. Depot bromperidol decanoate for schizophrenia. Wong, D., Adams, C.E., David, A., Quraishi, S.N. Cochrane database of systematic reviews (Online) (2004) [Pubmed]
  16. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. De Cuyper, H., Bollen, J., van Praag, H.M., Verstraeten, D. The British journal of psychiatry : the journal of mental science. (1986) [Pubmed]
  17. Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins. Nambu, K., Miyazaki, H., Nakanishi, Y., Oh-e, Y., Matsunaga, Y., Hashimoto, M. Biochem. Pharmacol. (1987) [Pubmed]
  18. Comparative bioavailability study of two haloperidol decanoate containing products. van Weringh, G., Komen, B.J., Thieme, R.E., van der Hoeven, R.T., Vos, T. Pharmacy world & science : PWS. (1994) [Pubmed]
  19. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Ereshefsky, L., Saklad, S.R., Tran-Johnson, T., Toney, G., Lyman, R.C., Davis, C.M. Psychopharmacology bulletin. (1990) [Pubmed]
  20. Morphological changes in met(5)-enkephalin-immunoreactive synaptic boutons in the rat neostriatum after haloperidol decanoate treatment. Mijnster, M.J., Ingham, C.A., Meredith, G.E., Docter, G.J., Arbuthnott, G.W. Eur. J. Neurosci. (1996) [Pubmed]
  21. Long-term treatment with haloperidol decreases the mRNA levels of complexin I, but not complexin II, in rat prefrontal cortex, nucleus accumbens and ventral tegmental area. Nakahara, T., Motomura, K., Hashimoto, K., Ueki, H., Gotoh, L., Hondo, H., Tsutsumi, T., Kuroki, T., Hirano, M., Uchimura, H. Neurosci. Lett. (2000) [Pubmed]
  22. Acute and chronic haloperidol treatments increase parkin mRNA levels in the rat brain. Nakahara, T., Gotoh, L., Motomura, K., Kawanami, N., Ohta, E., Hirano, M., Uchimura, H. Neurosci. Lett. (2001) [Pubmed]
  23. Regional brain changes in [3H]SCH 23390 binding to dopamine D1, receptors after long-term haloperidol treatment: lack of correspondence with the development of vacuous chewing movements. Sasaki, T., Kennedy, J.L., Nobrega, J.N. Behav. Brain Res. (1998) [Pubmed]
  24. Chronic haloperidol treatment attenuates receptor-mediated phosphoinositide turnover in rat brain slices. Li, R., Wing, L.L., Shen, Y., Wyatt, R.J., Kirch, D.G., Chuang, D.M. Neurosci. Lett. (1991) [Pubmed]
  25. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Chouinard, G., Annable, L., Campbell, W. Journal of clinical psychopharmacology. (1989) [Pubmed]
  26. Efficacy of olanzapine and haloperidol in an animal model of mania. El-Mallakh, R.S., Decker, S., Morris, M., Li, X.P., Huff, M.O., El-Masri, M.A., Levy, R.S. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) [Pubmed]
  27. Pharmacokinetics of haloperidol decanoate in rats. Oh-e, Y., Miyazaki, H., Matsunaga, Y., Hashimoto, M. J. Pharmacobio-dyn. (1991) [Pubmed]
  28. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. Wiles, D.H., McCreadie, R.G., Whitehead, A. Psychopharmacology (Berl.) (1990) [Pubmed]
  29. Expression of Fos protein in the limbic regions of the rat following haloperidol decanoate. Sun, Y.J., Suzuki, M., Kurachi, T., Murata, M., Kurachi, M. Brain Res. (1998) [Pubmed]
  30. Depot haloperidol decanoate for schizophrenia. Quraishi, S., David, A. Cochrane database of systematic reviews (Online) (2000) [Pubmed]
  31. Differential effects of haloperidol decanoate, a long-acting neuroleptic, in behavioral and biochemical tests. Oka, M., Karasawa, T., Ochi, Y., Asano, K., Terauchi, Y., Kadokawa, T. Archives internationales de pharmacodynamie et de thérapie. (1985) [Pubmed]
  32. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Kane, J.M., Davis, J.M., Schooler, N., Marder, S., Casey, D., Brauzer, B., Mintz, J., Conley, R. The American journal of psychiatry. (2002) [Pubmed]
  33. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. Kane, J.M. Journal of clinical psychopharmacology. (1986) [Pubmed]
  34. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. Shoham, S., Mazeh, H., Javitt, D.C., Heresco-Levy, U. Brain Res. (2004) [Pubmed]
  35. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate. Gelders, Y.G. International clinical psychopharmacology. (1986) [Pubmed]
 
WikiGenes - Universities